keyword
MENU ▼
Read by QxMD icon Read
search

Surgery ovarian cancer

keyword
https://www.readbyqxmd.com/read/28823141/targeted-therapy-of-ovarian-cancer-including-immune-check-point-inhibitor
#1
Jin Young Kim, Chi Heum Cho, Hong Suk Song
Epithelial ovarian cancer is the eighth most common cause of cancer-related deaths in women because most patients present with advanced stage disease at the time of diagnosis. Although cytoreductive surgery and platinum-based chemotherapy remain the gold standards of treatment, the recurrence rate of ovarian cancer remains high. Attempts to improve this standard two-drug chemotherapy by adding a third cytotoxic drug have failed to affect either progression-free survival or overall survival and have resulted in an increase in toxic side effects...
August 22, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28822556/associations-between-residual-disease-and-survival-in-epithelial-ovarian-cancer-by-histologic-type
#2
Alexander Melamed, Beryl Manning-Geist, Amy J Bregar, Elisabeth J Diver, Annekathryn Goodman, Marcela G Del Carmen, John O Schorge, J Alejandro Rauh-Hain
OBJECTIVE: Surgical cytoreduction has been postulated to affect survival by increasing the efficacy of chemotherapy in ovarian cancer. We hypothesized that women with high-grade serous ovarian cancer, which usually responds to chemotherapy, would derive greater benefit from complete cytoreduction than those with histologic subtypes that are less responsive to chemotherapy, such as mucinous and clear cell carcinoma. METHODS: We conducted a retrospective cohort study of patients who underwent primary cytoreductive surgery and adjuvant chemotherapy for stage IIIC or IV epithelial ovarian cancer from 2011 to 2013 using data from the National Cancer Database...
August 16, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28819441/vsv-based-virotherapy-in-ovarian-cancer-the-past-the-present-and-%C3%A2-future
#3
REVIEW
Beata Urszula Orzechowska, Marcin Jędryka, Katarzyna Zwolińska, Rafał Matkowski
The standard approach to treating patients with advanced epithelial ovarian cancer (EOC) after primary debulking surgery remains taxane and platinum-based chemotherapy. Despite treatment with this strategy, the vast majority of patients relapse and develop drug-resistant metastatic disease that may be driven by cancer stem cells (CSCs) or cancer initiating cells (CICs). Oncolytic viruses circumvent typical drug-resistance mechanisms, therefore they may provide a safe and effective alternative treatment for chemotherapy-resistant CSCs/CICs...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28818705/hormone-replacement-therapy-after-risk-reducing-salpingo-oophorectomy-minimises-endocrine-and-sexual-problems-a-prospective-study
#4
Ravi F M Vermeulen, Marc van Beurden, Jacobien M Kieffer, Eveline M A Bleiker, Heiddis B Valdimarsdottir, Leon F A G Massuger, Marian J E Mourits, Katja N Gaarenstroom, Eleonora B L van Dorst, Hans W H M van der Putten, Neil K Aaronson
BACKGROUND: There has been some doubts raised in earlier studies about the efficacy of hormone replacement therapy (HRT) in reducing endocrine and sexual problems in women who have undergone a risk-reducing salpingo-oophorectomy (RRSO). METHODS: In this prospective, observational study, we recruited 178 premenopausal women with a high risk for ovarian cancer. Fifty-seven women opted for RRSO and 121 for gynaecological screening (GS). Women completed questionnaires before surgery (T1) and 3 (T2) and 9 (T3) months post surgery, or at equivalent time points for the GS-group...
August 14, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28806962/oncofertility-in-patients-with-stage-i-epithelial-ovarian-cancer-fertility-sparing-surgery-in-young-women-of-reproductive-age
#5
Xuan Jiang, Jiaxin Yang, Mei Yu, Weimin Xie, Dongyan Cao, Ming Wu, Lingya Pan, Huifang Huang, Yan You, Keng Shen
BACKGROUND: Fertility-sparing surgery is indicated for patients with stage I epithelial ovarian cancers. We sought to evaluate the clinical outcomes and oncofertility in a cohort of patients of reproductive age with stage I epithelial ovarian cancer (EOC). METHODS: Overall, 108 patients of reproductive age (≤ 40 years) diagnosed with stage I EOC who were treated at Peking Union Medical College Hospital between 1999 and 2013 were included in the study. The Kaplan-Meier model and Cox regression analyses were used for the survival analysis...
August 15, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28804629/clinical-presentation-and-treatment-of-gastric-metastasis-from-other-malignancies-of-solid-organs
#6
Tsutomu Namikawa, Eri Munekage, Maho Ogawa, Toyokazu Oki, Masaya Munekage, Hiromichi Maeda, Hiroyuki Kitagawa, Takeki Sugimoto, Michiya Kobayashi, Kazuhiro Hanazaki
The aim of the present study was to analyze the clinicopathologic features and treatment outcomes of gastric metastasis from other malignancies of solid organs. A review was conducted of patients with metastatic tumors in the stomach from other malignancies of solid organs detected endoscopically at the Department of Surgery, Kochi Medical School, from January 1991 to December 2015. Seven patients (four men and three women), with a median age of 64 years (range, 42-71 years), had metastatic gastric tumors. Median tumor size was 7...
August 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28800941/survival-and-safety-associated-with-aggressive-surgery-for-stage-iii-iv-epithelial-ovarian-cancer-a-single-institution-observation-study
#7
Shinichi Tate, Kazuyoshi Kato, Kyoko Nishikimi, Ayumu Matsuoka, Makio Shozu
OBJECTIVE: We evaluated the efficacy and safety of aggressive surgery for advanced ovarian cancer at a non-high-volume center. MATERIALS AND METHODS: We evaluated consecutive patients with stage III/IV ovarian, fallopian, and peritoneal cancer undergoing elective aggressive surgery from January 2008 to December 2012, which encompassed the first 5years after implementing an aggressive surgery protocol. After receiving appropriate training for 9months, a gynecological surgical team began performing multi-visceral resections...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28800940/neoadjuvant-chemotherapy-and-chemotherapy-cycle-number-a-national-multicentre-study
#8
Alon D Altman, Jacob McGee, Taymaa May, Kelly Lane, Lin Lu, Wei Xu, Prafull Ghatage, Barry Rosen
OBJECTIVES: Six cycles of consolidation chemotherapy have become the standard for ovarian cancer treatment regimen following primary cytoreduction, yet with neoadjuvant chemotherapy (NAC), only 3 consolidation cycles are used. This study examines the effects of number of chemotherapy cycles in women with ovarian cancer that are being treated with neoadjuvant chemotherapy. In addition, we examined the effect of number of cycles on survival on consolidation and total chemotherapy. METHODS: All patients with stage IIIC and IV high grade serous carcinoma (HGSC) were identified at 4 major Canadian cancer centers treated with NAC...
August 8, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28795373/implementation-of-extensive-cytoreduction-resulted-in-improved-survival-outcomes-for-patients-with-newly-diagnosed-advanced-stage-ovarian-tubal-and-peritoneal-cancers
#9
Francesco Raspagliesi, Giorgio Bogani, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Chiara Borghi, Cono Scaffa, Federica Morano, Giuseppa Maltese, Domenica Lorusso
BACKGROUND: Residual disease (RD) after primary debulking surgery (PDS) is one of the main factors driving ovarian cancer prognosis. The primary end point of this study was assessment of the impact that surgery had on survival outcomes for patients with advanced ovarian cancer. METHODS: Data on the effect of newly diagnosed advanced-stage ovarian, tubal, and peritoneal cancers were analyzed during two study periods (T1: 2001-2006 and T2: 2007-2012), in which the concepts of optimal and complete cytoreduction were introduced and implemented...
August 9, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28794804/brca-mutation-in-ovarian-cancer-testing-implications-and-treatment-considerations
#10
REVIEW
Robert T Neff, Leigha Senter, Ritu Salani
Ovarian cancer is a heterogeneous disease that encompasses a number of different cellular subtypes, the most common of which is high-grade serous ovarian cancer (HGSOC). Still today, ovarian cancer is primarily treated with chemotherapy and surgery. Recent advances in the hereditary understanding of this disease have shown a significant role for the BRCA gene. While only a minority of patients with HGSOC will have a germline BRCA mutation, many others may have tumor genetic aberrations within BRCA or other homologous recombination proteins...
August 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28791708/exosomal-dnmt1-mediates-cisplatin-resistance-in-ovarian-cancer
#11
Ya-Lei Cao, Ting Zhuang, Bao-Heng Xing, Na Li, Qin Li
Ovarian cancer is the most common malignancy in women. Owing to late syndromic presentation and lack of efficient early detection, most cases are diagnosed at advanced stages. Surgery and platinum-based chemotherapy are still the standard care currently. However, resistance invoked often compromises the clinical value of the latter. Expression of DNA methyltransferase 1 (DNMT1) was analysed by gene array. Protein was determined by immunoblotting. Exosome was isolated with commercial kit. Cell proliferation was measured by CCK8 method...
August 8, 2017: Cell Biochemistry and Function
https://www.readbyqxmd.com/read/28791266/prognostic-assessment-of-sarcomatous-histologic-subtypes-of-ovarian-carcinosarcoma
#12
Hyun Jin Kim, Hyun-Mi Lee, Mi Kyung Kim, Yoo-Kyung Lee, In-Ho Lee, Ki-Heon Lee, Hyesun Kim
OBJECTIVE: Ovarian carcinosarcoma is a rare subtype of this disease that has not been thoroughly investigated. The aim of this study was to evaluate the prognostic factors and out comes in patients with ovarian carcinosarcoma. METHODS: All patients with histologically confirmed ovarian carcinosarcoma who were treated at Cheil General Hospital and Women's Healthcare Center between January 2000 and December 2015 were identified and analyzed. Data were extracted from medical records, and statistical analyses were performed to determine correlations between clinicopathological parameters and survival outcomes...
July 2017: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/28780755/when-to-consider-risk-reducing-mastectomy-in-brca1-brca2-mutation-carriers-with-advanced-stage-ovarian-cancer-a-case-study-illustrating-the-genetic-counseling-challenges
#13
Beverley Speight, Marc Tischkowitz
Germline mutations in BRCA1/BRCA2 significantly increase the risk of breast and ovarian cancer in women. This case report describes a BRCA1 germline mutation identified in a woman with stage IV epithelial ovarian cancer and the provision of genetic counseling about BRCA1-associated breast cancer risk in the three years following diagnosis. The report centers on the patient's enquiry about risk-reducing breast surgery. We focus on the challenges for health professionals and patients in understanding and balancing the risks and benefits of major prophylactic surgery in the context of a potentially life-limiting cancer diagnosis...
August 5, 2017: Journal of Genetic Counseling
https://www.readbyqxmd.com/read/28774461/phase-ii-trial-of-bevacizumab-with-dose-dense-paclitaxel-as-first-line-treatment-in-patients-with-advanced-ovarian-cancer
#14
Nicole D Fleming, Robert L Coleman, Celestine Tung, Shannon N Westin, Wei Hu, Yunjie Sun, Priya Bhosale, Mark F Munsell, Anil K Sood
OBJECTIVES: To assess the tolerability and efficacy of bevacizumab with carboplatin and weekly paclitaxel as first-line adjuvant therapy for advanced stage ovarian cancer. METHODS: After IRB approval, this single-institution, phase II study enrolled patients with stage III or IV epithelial ovarian cancer after primary cytoreductive surgery to treatment with carboplatin (AUC 5), weekly paclitaxel (80mg/m2), and bevacizumab (15mg/kg) every 3weeks for at least 6cycles...
July 31, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28772202/the-role-of-surgical-excision-for-the-krukenberg-tumour-a-case-report
#15
David Lam, Eugene Ong
INTRODUCTION: Krukenberg tumour (KT), which represents carcinoma in the ovary, is an uncommon manifestation of metastatic colorectal cancer. It is associated with poor prognosis and a high incidence of peritoneal metastatic disease. PRESENTATION OF CASE: The authors present a case of a 51-year-old female who had a symptomatic, metachronous right ovarian KT diagnosed 12 months after her initial resection. Surgery was performed to excise the 23cm tumour as well as the contralateral ovary and isolated peritoneal disease, with an R0 resection achieved...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28768570/primary-cytoreductive-surgery-and-adjuvant-hormonal-monotherapy-in-women-with-advanced-low-grade-serous-ovarian-carcinoma-reducing-overtreatment-without-compromising-survival
#16
Amanda N Fader, Jennifer Bergstrom, Amelia Jernigan, Edward J Tanner, Kara Long Roche, Rebecca L Stone, Kimberly L Levinson, Stephanie Ricci, Stephanie Wethingon, Tian-Li Wang, Ie-Ming Shih, Bin Yang, Gloria Zhang, Deborah K Armstrong, Stephanie Gaillard, Chad Michener, Robert DeBernardo, Peter G Rose
OBJECTIVES: Women with advanced-stage, low-grade serous ovarian carcinoma (LGSC) have low chemotherapy response rates and poor overall survival. Most LGSC tumors overexpress hormone receptors, which represent a potential treatment target. Our study objective was to determine the outcomes of patients with advanced-stage LGSC treated with primary cytoreductive surgery (CRS) and hormone therapy (HT). METHODS: A retrospective study was performed at two academic cancer centers...
July 30, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28766223/differences-among-a-modern-cohort-of-brca-mutation-carriers-choosing-bilateral-prophylactic-mastectomies-compared-to-breast-surveillance
#17
Elizabeth Gilbert, Emily C Zabor, Michelle Stempel, Debra Mangino, Alexandra Heerdt, Melissa Pilewskie
BACKGROUND: Women with a BRCA mutation have significantly elevated breast cancer risk, which can be reduced by >90% with bilateral prophylactic mastectomy (BPM). We sought to compare a cohort of BRCA mutation carriers choosing BPM versus breast surveillance to better elucidate factors that may impact decision making. METHODS: Women with a BRCA mutation were retrospectively identified from a prospectively maintained database. The surveillance cohort (n = 313) consisted of women seen in a high-risk clinic between 2014 and 2016, while the surgery cohort (n = 142) consisted of women who underwent BPM between 2010 and 2016...
August 1, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28763365/ultrasound-guided-laparoscopic-ovarian-wedge-resection-in-recurrent-serous-borderline-ovarian-tumours
#18
Benjamin P Jones, Srdjan Saso, Jessica Farren, Mona El-Bahrawy, Sadaf Ghaem-Maghami, J Richard Smith, Joseph Yazbek
OBJECTIVE: The aim of this study was to demonstrate the use of intraoperative ultrasound-guided ovarian wedge resection in the treatment of recurrent serous borderline ovarian tumors (sBOTs) that are too small to be visualized laparoscopically. METHODS: This was a prospective analysis of all women with recurrent sBOTs that were not visible laparoscopically, who underwent intraoperative ultrasound-guided ovarian wedge resection between January 2015 and December 2016 at the West London Gynaecological Cancer Centre, Imperial College NHS Trust, London, United Kingdom...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28763362/survival-after-primary-debulking-surgery-compared-with-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer-a-national-cancer-database-study
#19
Brandon-Luke L Seagle, Stephen Graves, Anna E Strohl, Shohreh Shahabi
OBJECTIVE: The aim of this study was to compare overall survival (OS) of women with advanced ovarian cancer treated with primary debulking surgery (PDS) or neoadjuvant chemotherapy (NAC) using a large national cohort. METHODS: The 1998-2011 National Cancer Database was queried to identify women with stage III or IV ovarian cancer treated with multiagent chemotherapy and stage-appropriate surgery. Overall survival was estimated and compared using Kaplan-Meier analysis between women who received PDS followed by multiagent chemotherapy or NAC followed by interval surgery...
August 1, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28760628/laparoscopic-minimally-invasive-approach-to-sentinel-lymph-node-mapping-of-the-ovary-using-the-near-infrared-fluorescent-s1-hd-pinpoint-system-with-indocyanine-green-dye
#20
Alessandro Buda, Paolo Passoni, Claudio Reato, Giampaolo Di Martino
STUDY OBJECTIVE: To show a novel minimally invasive approach to sentinel lymph node (SLN) detection of the ovary with the near-infrared guided-surgery using indocyanine green (ICG). DESIGN: step by step description of the technique with video and figures (educational video). SETTING: The standard surgical staging of early stage I-II ovarian cancer include systematic pelvic and aortic lymphadenectomy, even in the absence of clear evidence regarding the survival benefits associated with comprehensive retroperitoneal staging...
July 28, 2017: Journal of Minimally Invasive Gynecology
keyword
keyword
55599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"